Liquidia Corp(US:LQDA) Globenewswire·2025-10-27 12:30Core Viewpoint - Liquidia Corporation is set to report its third quarter 2025 financial results on November 3, 2025, and will host a webcast to discuss these results and provide a corporate update [1]. Group 1: Company Overview - Liquidia Corporation is a biopharmaceutical company focused on developing innovative therapies for patients with rare cardiopulmonary diseases [3]. - The company is currently developing and commercializing products for pulmonary hypertension using its proprietary PRINT Technology [3]. - Liquidia's approved product, YUTREPIA™ (treprostinil) inhalation powder, is used for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PHILD) [3]. - The company is also working on L606, an investigational sustained-release formulation of treprostinil, which is administered twice daily with a next-generation nebulizer [3]. - Additionally, Liquidia markets a generic version of Treprostinil Injection for PAH treatment [3]. Group 2: Webcast Information - The upcoming webcast will be available on Liquidia's website and will be archived for one year [2].